# A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

> **NCT05348785** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biogen** · enrollment: 650 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** BIIB122
- **DRUG:** BIIB122-Matching Placebo

## Key facts

- **NCT ID:** NCT05348785
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-19
- **Primary completion:** 2026-02-25
- **Final completion:** 2026-03-09
- **Target enrollment:** 650 (ACTUAL)
- **Last updated:** 2025-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05348785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05348785, "A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05348785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*